On the mechanism underlying calcein-induced cytotoxicity

European Journal of Pharmacology

Volumn 383, Issue 3, 1999, Pages 321-329

  Liminga, Gunnar ^a   Jonsson, Bertil ^a   Nygren, Peter ^a   Larsson, Rolf ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Calcein; Calcein AM; Cytosensor ; Cytotoxicity; U 937 GTB

Indexed keywords

ACRIDINE ORANGE; ANTINEOPLASTIC AGENT; CALCEIN; CISPLATIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; IDARUBICIN; MITOCHONDRIAL DNA; MITOXANTRONE; OXIDOREDUCTASE; PACLITAXEL; RHODAMINE 123; TOPOTECAN; VINCRISTINE; ZINOSTATIN;

ACIDIFICATION; APOPTOSIS; ARTICLE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; FLUORESCENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL;

EID: 0032764004     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00655-X     Document Type: Article

References (48)

1. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbot D.L., Mayo G.H., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:1988;589-601.
2. 3H] thymidine incorporation assay. J. Immunol. Methods. 170:1994;211-224.
3. Beck W.T., Mueller T.J., Tanzer L.R. Altered surface membrane glycoproteins in vinca alcaloid-resistant human leukemic lymphoblasts. Cancer Res. 39:1979;2070-2076.
4. Bernal S.D., Lampidis T.J., Summerhayes I.C., Chen L.B. Rhodamine-123 selectively reduces clonal growth of carcinoma cells in vitro. Science. 218:1982;117-119.
5. Borden E.C., Hogan T.F., Voelkel J.G. Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res. 42:1982;4948-4953.
6. Botling J., Liminga G., Larsson R., Nygren P., Nilsson K. Development of vincristine resistance and increased sensitivity to cyclosporin a and verapamil in the human U-937 lymphoma cell line without overexpression to the 170 kDa P-glycoprotein. Int. J. Cancer. 58:1994;269-274.
7. Boyd M.R., Paull K.D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34:1995;91-109.
8. Cavalli L.R., Varella-Garcia M., Liang B.C. Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ. 8:1997;1189-1198.
9. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almqvist K.C., Stewart A.J., Kurz E.U., Duncan A.M.V., Deeley R.G. Over-expression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1654.
10. Colton T. Regression and correlation. Statistics in Medicine. 1974;189-217 Little Brown and Company, Boston.
11. Dalton W.S., Durie B.G.M., Alberts D.S., Gerlach J.H., Cress A.E. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res. 46:1986;5125-5130.
12. Danks M.K., Yalowich J.C., Beck W.T. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 47:1987;1297-1301.
13. Davis S., Weis M.J., Wong J.R., Lampidis T.J., Chen L.B. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of Rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J. Biol. Chem. 260:1985;13844-13850.
14. Dhar S., Nygren P., Csoka K., Botling J., Nilsson K., Larsson R. Anti-cancer drug characterisation using a human tumor cell line panel representing defined types of drug resistance. Br. J. Cancer. 74:1996;888-896.
15. Dhar S., Nygren P., Liminga G., Sundström C., de la Torre M., Nilsson K., Larsson R. Relationship between cytotoxic drug response patterns and activity of drug efflux transporters mediating multidrug resistance. Eur. J. Pharmacol. 346:1998;315-322.
16. Dorward A., Sweet S., Moorehead R., Singh G. Mitochondrial contributions to cancer cell physiology: redox balance, cell cycle and drug resistance. J. Bioenerg. Biomem. 29:1997;385-392.
17. Ekelund S., Nygren P., Larsson R. Microphysiometry: new technology for evaluation of anticancer drug activity in human tumor cells in vitro. Anti-Cancer Drugs. 9:1998;531-538.
18. Goldberg I.H., Kappen L.S., Povirk L.F., Chin D.H. Molecular mechanism of novel DNA sugar damage by an antitumour protein antibiotic. Drugs Exp. Clin. Res. XII(6-7):1986;495-505.
19. Haugland R.P. Handbook of Fluorescent Probes and Research Chemicals. 1997;Molecular Probes, Eugene, OR.
20. Homoloya L., Holló Z., Germann U.A., Pastan I., Gottesman M.M., Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 268:1993;21493-21496.
21. Hüser J., Rechenmacher C.E., Blatter L.A. Imaging the permeability pore transition in single mitochondria. Biophys. J. 74:1998;2129-2137.
22. Johnson L.V., Walsh M.L., L.B. C. Localization of mitochondria in living cells with rhodamine 123. Proc. Natl. Acad. Sci. USA. 77:1980;990-994.
23. Jonsson B., Liminga G., Csoka K., Fridborg H., Dhar S., Nygren P., Larsson R. Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours. Eur. J. Cancer. 32A:1996;883-887.
24. Kroemer G., Dallaporta B., Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Ann. Rev. Phys. 60:1998;619-642.
25. Lampidis T.J., Bernal S.D., Summerhayes I.C., Chen L.B. Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Cancer Res. 43:1983;716-720.
26. Lampidis T.J., Podona T., Israel M., Safa A.R., Lothstein L., Savaraj N., Tapiero H., Priebe W. Circumvention of P-gp mdr as a function of anthracycline lipophilicity and charge. Biochemistry. 36:1997;2679-2685.
27. Lampidis T.J., Podona T., Kolonias D., Hu Y.P., Savaraj N., Moraes C.T. 90th annual meeting of AACR Use of a mitochondrial mutant cell line for probing anti-cancer drug targets. 40:1999;AACR, Philadelphia, PA. ed., Abstr 4389.
28. Larsson R., Kristensen J., Sandberg C., Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer. 50:1992;177-185.
29. Liminga G., Nygren P., Larsson R. Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. Exp. Cell Res. 212:1994;291-296.
30. Liminga G., Nygren P., Dhar S., Nilsson K., Larsson R. Cytotoxic effect of calcein acetoxymethyl ester on human tumor cell lines: Drug delivery by intracellular trapping. Anti-Cancer Drugs. 6:1995;578-585.
31. Lin J.-H., Castora F.J. DNA topoisomerase II from mammalian mitochondria is inhibited by the antitumor drugs, m-Amsa and VM-26. Biochem. Biophys. Res. Commun. 176:1991;690-697.
32. Maftah A., Petit J.M., Ratinaud M.-H., Julien R. 10-N nonyl-acridine orange: a fluorescent probe which stains mitochondria independently of their energetic state. Biochem. Biophys. Res. Commun. 164:1989;185-190.
33. McConnell H.M., Owicki J.C., Parce J.W., Miller D.L., Baxter G.T., Wada H.G., Pitchford S The Cytosensor microphysiometer: biological applications of silicon technology. Science. 257:1992;1906-1912.
34. Minamikawa T., Williams D.A., Bowser D.N., Nagley P. Mitochondrial permeability transition and swelling can occur reversibly without inducing cell death in intact human cells. Exp. Cell Res. 246:1999;26-37.
35. Mirski S.E.L., Gerlach J.H., Cole S.P.C. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res. 47:1987;2594-2598.
36. Modica-Napolitano J.S., Aprille J.R. Basis for the selective cytotoxicity of rhodamine 123. Cancer Res. 47:1987;4361-4365.
37. Mulcahy R.T., Bailey H.H., Gipp J.J. Up-regulation of gamma-glutamylcysteine synthase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother. Pharmacol. 34:1994;67-71.
38. Napier M.A., Goldberg I.H. Neocarzinostatin chromophore. Assignment of spectral properties and structural requirements for binding to DNA. Mol. Pharmacol. 23(2):1983;500-510.
39. Nieminen A.-L., Saylor A.K., Tesfai S.A., Herman B., Lemasters J.J. Contribution of the mitochondrial permeability transition to a lethal injury after exposure of hepatocytes to t-butylhydroperoxide. Biochem. J. 307:1995;99-106.
40. Nieminen A.-L., Byrne A.M., Herman B., Lemasters J.J. Mitochondrial permeability transition in hepatocytes induced by t-BuOOH: NAD(P)H and reactive oxygen species. Am. J. Physiol. 1997;C1286-C1294.
41. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., Boyd M.R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and compare algorithm. J. Natl. Cancer Inst. 81:1989;1088-1092.
42. Petronilli V., Miotto G., Colonna R., Bernardi P. Tetramethylrhodamine quenching of calcein fluorescence limits the evaluation of the intracellular distribution of calcein. Biophys. J. 72:1997;. Abstract.
43. Smith P.J., Sykes H.R., Fox M.E., Furlong I.J. Subcellular localisation of the anticancer compound drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage. Cancer Res. 52:1992;4000-4008.
44. Sun X., Wong J.R., Song K., Hu J., Garlid K.D., Chen L.B. AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor activity. Cancer Res. 54:1994;1465-1471.
45. Sundström C., Nilsson K. Establishment and Characterisation of a Human Histiocytic Lymphoma Cell Line (U-937). Int. J. Cancer. 17:1976;565-577.
46. Teicher B.A. Anticancer drug development guide; preclinical screening, clinical trials and approval. 1997;Humana Press, Totowa, NJ.
47. Teicher B.A. Cancer therapeutics: experimental and clinical agents. 1997;Humana Press, Totowa, NJ.
48. Versantvoort C.H.M., Bagrij T., Wright K.A., Twentyman P.R. On the relationship between probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP). Int. J. Cancer. 63:1995;855-862.